Logotype for Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries (TEVA) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Teva Pharmaceutical Industries Limited

Q3 2026 earnings summary

3 Nov, 2026

Executive summary

  • Q3 revenue was $4.395B, down 2% YoY; innovative brands grew 33% in local currency, partly offsetting lower generic revenue, led by lenalidomide erosion.

  • Non-GAAP gross margin rose to 58.7% (+345 bps) and non-GAAP EPS to $0.86 (+10%); GAAP net income was $233M versus $433M a year earlier.

  • 2026 revenue and key brand outlooks were raised; WELTRUZA approval, biosimilar partnerships and pipeline progress supported the growth strategy.

Financial highlights

  • GAAP gross profit rose 6% to $2.440B and gross margin was 55.5% versus 51.4%; GAAP operating income was $714M versus $882M.

  • Non-GAAP operating income was $1.393B (+8%), with a 31.7% margin (+282 bps); non-GAAP net income was $1.013B and diluted EPS $0.86 versus $0.78.

  • Adjusted EBITDA grew 7% to $1.496B; free cash flow was $495M (-4%), while Q3 YTD free cash flow reached $1.305B (+19%).

  • Q3 revenue was $4.395B; 9M revenue was $12.519B, flat YoY, while 9M net income attributable fell to $26M from $930M.

Outlook and guidance

  • FY2026 revenue guidance rose to $16.7B-$17.0B; non-GAAP operating income is $3.8B-$3.9B and adjusted EBITDA $4.23B-$4.43B.

  • FY2026 diluted EPS guidance is $1.92-$2.11 and free cash flow $2.1B-$2.4B; guidance includes $0.87B acquired IPR&D charges in operating income and EBITDA.

  • 2026 outlooks rose to $2.55B-$2.65B for AUSTEDO, $930M-$960M for AJOVY and $290M-$310M for UZEDY.

  • 2027 targets include mid-single-digit 2023-27 revenue CAGR, 30% non-GAAP operating margin, 2.0x net debt/adjusted EBITDA and 80% cash-to-earnings; gross margin outlook is 57%-58%.

  • Transformation programs target ~$700M net savings and an ~8% workforce reduction from the 2024 baseline by end-2027; two-thirds of savings are expected in 2026.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Teva Pharmaceutical Industries